These press releases are for business and financial media.
-
- 04 May 2006
- AstraZeneca Discontinues Development of GALIDA TM (tesaglitazar) AstraZeneca today announced the discontinuation of the GALIDA development programme. GALIDA is a dual PPAR alpha and gamma agonist and was in phase III development for the treatment of the glucose and lipid abnormalities associated with type 2 diabetes.
-
- 27 April 2006
- First quarter results 2006 "A strong first quarter, with sales up 12 percent and Earnings per Share up 40 percent. Targets for the full year increased."
-
- 27 April 2006
- AstraZeneca and Abraxis BioScience to co-promote cancer therapy ABRAXANE; Abraxis BioScience to acquire AstraZeneca’s U.S Anaesthetic and Analgesic Product Portfolio AstraZeneca today announced an agreement with Abraxis BioScience Inc. (ABBI) to co-promote ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in the U.S. In addition to the co-promotion agreement for ABRAXANE®, AstraZeneca also announced the divestment of its US anaesthetics and analgesic products to Abraxis BioScience.
-
- 28 March 2006
- London Stock Exchange Announcement: AstraZeneca PLC Annual Information Update As required under the Prospectus (Directive 2003/71/EC) Regulations 2005 and paragraph 5.2 of the Prospectus Rules, and following publication of the Annual Report and Form 20-F Information on 28 February 2006, AstraZeneca PLC is presenting its first Annual Information Update in relation to information that has been published or made available to the public between 1 February 2005 and 27 March 2006.
-
- 20 March 2006
- London Stock Exchange Announcement: Notice Of Annual General Meeting 2006 And Proposed Board Changes AstraZeneca PLC announced today the publication of its Notice of Annual General Meeting for 2006 with a covering letter from the Chairman of the Board, and a Shareholders’ Circular and Proxy Form.
-
- 14 March 2006
- AstraZeneca Education Seminar on Merck arrangements On Tuesday, 14 March 2006 at 13:00GMT (14:00CET, 08:00EST) AstraZeneca will conduct an education seminar on the topic of the Company’s arrangements with Merck. Details for accessing the audio webcast of this seminar are listed below.
-
- 14 March 2006
- Headline Results From Chant Safety and Tolerability Study In Intracerebral Hemorrhage (Ich) Show NXY-059 Achieved Key Endpoints AstraZeneca today announced results from the phase IIb safety and tolerability trial for NXY-059 in acute intracerebral hemorrhage (ICH) patients, CHANT (Cerebral Hemorrhagic And NXY-059 Treatment). Although AstraZeneca is developing NXY-059 for the treatment of Acute Ischemic Stroke (AIS), it was felt important to assess the safety and tolerability of NXY-059 in ICH, as treatment may be initiated prior to a neuroimaging confirmation of the diagnosis of AIS. The data showed that the safety and tolerability
-
- 09 March 2006
- AstraZeneca commences patent infringement litigation against IVAX AstraZeneca announced today that it has filed a lawsuit in the United States District Court for the District of New Jersey against IVAX Corporation, IVAX Pharmaceuticals, Inc. and Zenith Laboratories, Inc. (collectively “IVAX”), and IVAX’s parent, Teva Pharmaceutical Industries Ltd. and its U.S. subsidiary, Teva Pharmaceuticals USA, for willful infringement of AstraZeneca’s patents protecting NEXIUM® (esomeprazole magnesium).
-
- 28 February 2006
- AstraZeneca Issues 2005 Annual Report AstraZeneca today published its 2005 Annual Report and Form 20-F Information, its 2005 Annual Review and its 2005 Corporate Responsibility Summary Report. These documents are available on the company’s website, www.astrazeneca.com/annualreport
-
- 16 February 2006
- AstraZeneca Files Notice Of Appeal For Patent Infringement On Toprol-XL® AstraZeneca announced today that is has filed a Notice with the US District Court for the Eastern District of Missouri of its appeal to the Court of Appeals for the Federal Circuit of the January 17, 2006 decision by Judge Rodney Sippel declaring US compound patent Number 5,081,154 and composition patent Number 5,001,161 covering TOPROL XL (metoprolol succinate) extended release tablets invalid and unenforceable.
-
- 14 February 2006
- AstraZeneca Decides to Withdraw Exanta™ AstraZeneca today announced that the company has decided to withdraw the anticoagulant Exanta™ (melagatran / ximelagatran) from the market and terminate its development. AstraZeneca estimates that approximately 400 patients are currently being prescribed the drug for short-term prevention of venous thromboembolism (VTE) following orthopaedic surgery (OS). Two ongoing Exanta clinical trials will be discontinued and Exanta-treated patients switched to other treatments. It is important that patients do not
-
- 09 February 2006
- ASTRAZENECA ANNOUNCES FIRST REGULATORY APPROVAL FOR NEW HFA pMDI FOR PULMICORT® February 9, 2006, Lund, Sweden. AstraZeneca announced today the approval in Finland, as the first approval in the first European market, of a new pressurised metered-dose inhaler (pMDI) formulation of the inhaled corticosteroid Pulmicort® (budesonide) for the treatment of asthma in adults and children. The currently available chlorofluorocarbon (CFC) pMDI formulation has been on the market since December 1981 and, in accordance with the Montreal Protocol, will be replaced by a non-ozone depleting
-
- 02 February 2006
- Fourth Quarter and Full Year Results 2005 AstraZeneca PLC Fourth Quarter and Full Year Results 2005
-
- 18 January 2006
- Toprol-XL® (metoprolol succinate): AstraZeneca to Appeal Decision in U.S. Patent Litigation AstraZeneca today announced that it has received a decision of Judge Rodney Sippel of the U.S. District Court for the Eastern District of Missouri in litigation titled In Re Metoprolol Succinate Patent Litigation. This case is a consolidation of the company’s cases against defendants KV Pharmaceutical Company, Andrx Pharmaceuticals LLC, Andrx Corporation, and Eon Labs Manufacturing, Inc. The decision was issued in response to motions by all parties argued on November 16-17, 2005, regarding the validity,
-
- 03 January 2006
- AstraZeneca Submits sNDA For Seroquel For Bipolar Depression Treatment Filing Seeks Approval of SEROQUEL as a Monotherapy Treatment for Bipolar Depression
Not signed in
Page tools
Share price
- London
-
26.95 GBP - New York
-
44.82 USD
- Stockholm
-
310.10 SEK
At 21-Nov-2009 10:43 GMT
Detailed share priceIntroduction to AstraZeneca
Our responsibility
We continue to communicate openly on a range of issues, including:
